University of Virginia
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, University of Virginia sits in the top decile of US sponsors by registered trial count (#78 of 15,742 sponsors by registered trial count).
University of Virginia: 449 sponsored US clinical trials, 101 recruiting.
University of Virginia sponsors 449 registered US clinical trials on ClinicalTrials.gov, 101 of them currently recruiting, and 281 completed. 40 of these trials are in Phase 3-4 (later-stage) and 109 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Type 1 Diabetes Mellitus, with 9 trials.
Top-decile sponsor footprint
University of Virginia ranks in the top decile of sponsors by registered trial count (#78 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
281 of 317 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (88.6%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
449 total, page 5 of 9
Bleeding in Hospitalized Patients With Liver Disease Undergoing Invasive Procedures
NCT04076605
Safety of Artificial Pancreas Therapy in Preschoolers, Age 2-6
NCT04084171
Undetectable IgE as a Sentinel Biomarker for Humoral Immunodeficiency
NCT03968211
Utilizing Helpline for Opioid Dependence Treatment
NCT03969238
ZILRETTA™ for Treatment of Idiopathic Adhesive Capsulitis
NCT04831255
A Study of t:Slim X2 With Control-IQ Technology
NCT03844789
A Tele-Health Symptom Management Program for Patients With Heart Failure: Pall-Heart
NCT04120857
Adherence to Medical Treatments for Telemedicine Patients
NCT04180475
Study to Test Efficacy of Real-time Reminders on Apple Watch To Decrease Late or Missed Meal Boluses
NCT03809858
NEO Rehab Program for Premature Infants at Risk for Cerebral Palsy
NCT04330859
Orthopaedic Surgical Wound Closure Comparison Study
NCT05251064
Using Smart Phone Technology to Support HIV Medication Refill Adherence in Virginia
NCT03876626
Neuromuscular Control in Individuals Following ACL-Reconstruction
NCT04495075
BATs in Patients With Breast Cancer and Leptomeningeal Metastases
NCT03661424
Effect of Hyperglycemia on Microvascular Perfusion in Healthy Adults
NCT03520569
A Pilot Study of the Combination of Entinostat With Capecitabine in High Risk Breast Cancer After Neo-adjuvant Therapy
NCT03473639
Interpretation Training to Reduce Anxiety: Evaluating Technology-based Delivery Models and Methods to Reduce Attrition
NCT03498651
CloudConnect: Predictive And Retrospective Clinical Decision Support For Chronic Disease Management
NCT03676465
The International Diabetes Closed Loop (iDCL) Trial: Clinical Acceptance of the Artificial Pancreas (DCLP3 Extension)
NCT03591354
Safety and Efficacy of Initializing the Control-IQ Artificial Pancreas System Using Total Daily Insulin
NCT03804983
Urine Colorimetry for Tuberculosis Pharmacokinetics Evaluation in Children and Adults
NCT05283967
Using Smart Phone Technology to Support PrEP Uptake and Adherence
NCT04868383
Use of an Internet-Based Insomnia Intervention to Prevent Cognitive Decline in Adults With Mild Cognitive Impairment
NCT04382365
Safety and Feasibility of an Insulin Sensitivity-Informed Bolus Calculator in Type 1 Diabetes
NCT03709108
Midodrine Use in Septic Shock
NCT03706053
Utilization of the Ketogenic Diet in Patient With Relapsing Remitting MS
NCT03718247
ViviGen Cellular Bone Matrix for Hindfoot or Ankle Arthrodesis
NCT04138017
The VRIF Trial: Hypoglycemia Reduction With Automated-Insulin Delivery System
NCT03674281
NEO Rehab for Infants at Risk of Cerebral Palsy
NCT03372590
Kids SipSmartER, an Intervention to Reduce Sugar-sweetened Beverages
NCT03740113
Benefits of Continuous Glucose Monitoring With GEM Lifestyle Modification for Adults With Type 2 Diabetes
NCT03207893
Hunger and Learning Study in Preschoolers
NCT03861208
The International Diabetes Closed Loop (iDCL) Trial: Clinical Acceptance of the Artificial Pancreas
NCT03563313
Pharmacokinetics of Single-Dose Liposomal Bupivacaine in Surgeon Performed Intercostal Nerve Blocks
NCT03708198
Prospective Comparison of Metolazone Versus Chlorothiazide for Acute Decompensated Heart Failure With Diuretic Resistance
NCT03574857
Glucagon Counterregulation in Type 1 Diabetes
NCT03547427
Prematurity-Related Ventilatory Control: Role in Respiratory Outcomes
NCT03174301
Phase I EGFR BATs in Newly Diagnosed Glioblastoma
NCT03344250
Sleep Healthy Using The Internet for Older Adult Sufferers of Insomnia and Sleeplessness
NCT03213132
CGM Use in Islet Transplant Recipients
NCT03427931
Is Adrenal Insufficiency Under-diagnosed in Hospitalized Cirrhosis Patients?
NCT03368066
Exercise Activity-Based Bolus Decisions in Type 1 Diabetes
NCT03394352
Artificial Pancreas and Remote Monitoring During a T1DM Youth Ski Camp
NCT03369067
Colonoscopy in the Prone Position for Patients With BMI Greater Than 30
NCT03337217
A Pilot Test of t:Slim X2 With Control-IQ Technology
NCT03368937
The International Diabetes Closed Loop (iDCL) Trial: Protocol 1
NCT02985866
Hallmarks of Protective Immunity in Sequential Rhinovirus Infections in Humans
NCT02796001
Human Milk and Infant Intestinal Microbiome Study
NCT03181269
A Trial of Alirocumab and Plaque Regression in Peripheral Arterial Disease
NCT02959047
Family Disclosure in Cascade Testing
NCT04168736
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 58 |
| Phase 2 | 51 |
| Phase 3 | 14 |
| Phase 4 | 26 |
Therapeutic Areas
What is open in the University of Virginia pipeline
101 recruiting of 449 indexed (22% open); 281 completed (63%).
Phase mix: 40 late (III/IV) vs 109 early (I/II) (early-phase heavy).
Top condition: Type 1 Diabetes Mellitus (9 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
University of Virginia: open-pipeline peers nationwide
Peers matched on 449 registered trials and 22% open enrollment, not the therapeutic-area sidebar.
University of Virginia sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 449 trials (± recruiting share)
- Medical College of Wisconsin · 447 trials · 21% recruiting
- Alliance for Clinical Trials in Oncology · 446 trials · 7% recruiting
- Boston Children's Hospital · 462 trials · 24% recruiting
- Children's Hospital of Philadelphia · 431 trials · 18% recruiting
Sponsors near 22% open enrollment (± trial volume)
- Ohio State University Comprehensive Cancer Center · 23% recruiting · 341 trials
- University of Delaware · 23% recruiting · 106 trials
- University of Oklahoma · 22% recruiting · 358 trials
- ALX Oncology · 22% recruiting · 9 trials
Related
What to do with this University of Virginia page
449 registered trials is a research-attention snapshot, not an endorsement of University of Virginia or any single study.
- 101 of University of Virginia's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Type 1 Diabetes Mellitus is the condition University of Virginia studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Type 1 Diabetes Mellitus trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
University of Virginia pipeline card: 449 registered trials from official public datasets.Report a data error.